Among the peptides discussed for body composition, tesamorelin holds a special place: it is one of the few that has traveled the entire road from laboratory idea to large randomized trials to an approved therapy. That makes it a genuinely satisfying story — and a wonderful reference point for what mature human evidence in this field can look like.
What it is
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). It works by stimulating the pituitary to release the body’s own growth hormone in its natural, pulsatile rhythm, rather than supplying growth hormone directly. The FDA approved it in 2010 (as Egrifta, later reformulated) to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
What the human trials showed
This is where tesamorelin shines as a case study. In a pooled analysis of roughly 800 participants across two randomized, placebo-controlled Phase III trials, tesamorelin reduced visceral adipose tissue by approximately 15% from baseline over 26 weeks — significantly more than placebo, and, notably, measured by CT imaging rather than a scale or a tape measure. Later research found the visceral-fat reduction was accompanied by improvements in liver fat and liver enzymes.
Three details make the evidence especially instructive:
The effect was specific — it reduced deep visceral fat, the metabolically active kind, without much change to subcutaneous fat. That specificity is a sign of a well-characterized mechanism.
The benefit tracked with continued treatment; when therapy stopped, visceral fat gradually returned. The peptide manages a condition rather than permanently resetting it — a clear, honest finding that the trials captured precisely.
And the outcomes were imaged and quantified, which is why the effect size can be trusted in a way that testimonials never allow.
Why it matters
Tesamorelin is valuable for what it is and for what it demonstrates. As a molecule, it is a well-understood, approved therapy for a specific population. As a model, it shows the field at its best: a clear mechanism, randomized controlled trials, imaging-based endpoints, and a candid account of exactly what the peptide does and does not do.
That standard is worth celebrating, because it is the standard the rest of peptide science is steadily working toward. Tesamorelin proves that peptides can and do earn rigorous human evidence — and it gives readers a concrete picture of what that evidence looks like when a molecule goes the full distance.